RxDoctor Payments Data

John Nan, MD

Interventional Cardiology · Newport Beach, CANPI 1013336643

Payments from drug & device makers

$12,050in general payments, 2019–2025

Across 76 payments — averaging $158.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$9K
  • Medtronic$2K
  • Boston Scientific$388
  • Novartis$212
  • Chiesi USA, Inc.$132
  • Cardiovascular Systems Inc.$124
  • plus $487 from 12 others

What the payments were for

  • Consulting fees$6,89057%
  • Grants$2022%
  • Travel & lodging$2,28919%
  • Food & beverage$2,52321%
  • Education$1451%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,050 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$468,815
Medicare patients
666
Services billed
3,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$259,530
XareltoRivaroxaban44$52,022
EntrestoSacubitril/Valsartan27$44,072
Repatha SureclickEvolocumab31$23,262
Praluent PenAlirocumab12$5,806
Metoprolol Succinate209$3,493
Valsartan32$1,069
Amiodarone Hcl35$948
Atorvastatin Calcium104$944
ClopidogrelClopidogrel Bisulfate74$938
Losartan Potassium78$865
Diltiazem 24hr Er (Xr)Diltiazem Hcl17$810
Amlodipine Besylate116$772
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$687
Rosuvastatin Calcium28$500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$53$52,02244 claims
NovartisEntresto$212$44,07227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →